Cyclacel Pharmaceuticals Inc (CYCC)

5.03
0.16 3.28
NASDAQ : Health Care
Prev Close 4.87
Open 5.14
Day Low/High 4.75 / 5.17
52 Wk Low/High 3.60 / 12.60
Volume 31.28K
Avg Volume 95.60K
Exchange NASDAQ
Shares Outstanding 3.01M
Market Cap 14.82M
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cyclacel Announces Reverse Stock Split

Cyclacel Announces Reverse Stock Split

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT --

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Cyclacel Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Cyclacel Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Cyclacel Pharmaceuticals, Inc.

Cyclacel Reviews 2015 Achievements And Announces Key Business Objectives For 2016

Cyclacel Reviews 2015 Achievements And Announces Key Business Objectives For 2016

Company to Present at the Biotech Showcase(TM) 2016 Conference

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models

In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST

Data To Be Presented On CYC065, Cyclacel's CDK2/9 Inhibitor, At AACR-NCI-EORTC International Conference

Data To Be Presented On CYC065, Cyclacel's CDK2/9 Inhibitor, At AACR-NCI-EORTC International Conference

Mechanistic Rationale of CYC065 in Targeted Solid Tumors and Hematology

Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results

Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results

Conference Call Scheduled August 11, 2015 at 4:30 p.m. EDT

First Patient Dosed In IST Of CDK Inhibitor Seliciclib In Cushing's Disease, A Serious Endocrine Disorder

First Patient Dosed In IST Of CDK Inhibitor Seliciclib In Cushing's Disease, A Serious Endocrine Disorder

- Unique Dual Action Through Inhibition of Cyclin E and ACTH Production in Pituitary Tumors -

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development Of Seliciclib In Cystic Fibrosis

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development Of Seliciclib In Cystic Fibrosis

Novel CDK Inhibitor-Based Approach to Treat Cystic Fibrosis

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks are ready to break out and trade higher from current levels.